169 related articles for article (PubMed ID: 37767562)
1. Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.
Safa FM; Rasmussen T; Fontan L; Xia M; Melnick A; Wiestner A; Lobelle-Rich P; Burger JA; Mouawad Y; Safah H; Flemington EK; Saba NS
Haematologica; 2024 May; 109(5):1348-1358. PubMed ID: 37767562
[TBL] [Abstract][Full Text] [Related]
2. Unlocking the therapeutic potential of targeting
Samiksha S; Chan LN
Haematologica; 2024 May; 109(5):1317-1319. PubMed ID: 37916388
[No Abstract] [Full Text] [Related]
3. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.
Dai B; Grau M; Juilland M; Klener P; Höring E; Molinsky J; Schimmack G; Aukema SM; Hoster E; Vogt N; Staiger AM; Erdmann T; Xu W; Erdmann K; Dzyuba N; Madle H; Berdel WE; Trneny M; Dreyling M; Jöhrens K; Lenz P; Rosenwald A; Siebert R; Tzankov A; Klapper W; Anagnostopoulos I; Krappmann D; Ott G; Thome M; Lenz G
Blood; 2017 Jan; 129(3):333-346. PubMed ID: 27864294
[TBL] [Abstract][Full Text] [Related]
4. MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas.
Minderman M; Lantermans HC; Grüneberg LJ; Cillessen SAGM; Bende RJ; van Noesel CJM; Kersten MJ; Pals ST; Spaargaren M
Blood Cancer J; 2023 Mar; 13(1):37. PubMed ID: 36922488
[TBL] [Abstract][Full Text] [Related]
5. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.
Hailfinger S; Lenz G; Ngo V; Posvitz-Fejfar A; Rebeaud F; Guzzardi M; Penas EM; Dierlamm J; Chan WC; Staudt LM; Thome M
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19946-51. PubMed ID: 19897720
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
8. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
[TBL] [Abstract][Full Text] [Related]
9. Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-κB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells.
Wu CH; Yang YH; Chen MR; Tsai CH; Cheng AL; Doong SL
PLoS One; 2018; 13(6):e0199779. PubMed ID: 29953499
[TBL] [Abstract][Full Text] [Related]
10. MALT1 protease: a new therapeutic target in B lymphoma and beyond?
McAllister-Lucas LM; Baens M; Lucas PC
Clin Cancer Res; 2011 Nov; 17(21):6623-31. PubMed ID: 21868762
[TBL] [Abstract][Full Text] [Related]
11. MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
Saba NS; Wong DH; Tanios G; Iyer JR; Lobelle-Rich P; Dadashian EL; Liu D; Fontan L; Flemington EK; Nichols CM; Underbayev C; Safah H; Melnick A; Wiestner A; Herman SEM
Cancer Res; 2017 Dec; 77(24):7038-7048. PubMed ID: 28993409
[TBL] [Abstract][Full Text] [Related]
12. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.
Fontán L; Qiao Q; Hatcher JM; Casalena G; Us I; Teater M; Durant M; Du G; Xia M; Bilchuk N; Chennamadhavuni S; Palladino G; Inghirami G; Philippar U; Wu H; Scott DA; Gray NS; Melnick A
J Clin Invest; 2018 Oct; 128(10):4397-4412. PubMed ID: 30024860
[TBL] [Abstract][Full Text] [Related]
13. MALT1 auto-proteolysis is essential for NF-κB-dependent gene transcription in activated lymphocytes.
Baens M; Bonsignore L; Somers R; Vanderheydt C; Weeks SD; Gunnarsson J; Nilsson E; Roth RG; Thome M; Marynen P
PLoS One; 2014; 9(8):e103774. PubMed ID: 25105596
[TBL] [Abstract][Full Text] [Related]
14. MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-κB activation.
Liu X; Yue C; Shi L; Liu G; Cao Q; Shan Q; Wang Y; Chen X; Li H; Wang J; Gao S; Niu M; Yu R
J Cell Mol Med; 2020 Jul; 24(13):7550-7562. PubMed ID: 32452133
[TBL] [Abstract][Full Text] [Related]
15. Z-VRPR-FMK can inhibit the growth and invasiveness of diffuse large B-cell lymphoma by depressing NF-κB activation and MMP expression induced by MALT1.
Feng J; Yang W; Wang J; Pu Z; Han Y; Wan L
Int J Clin Exp Pathol; 2019; 12(6):1947-1955. PubMed ID: 31934017
[TBL] [Abstract][Full Text] [Related]
16. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells.
Ho L; Davis RE; Conne B; Chappuis R; Berczy M; Mhawech P; Staudt LM; Schwaller J
Blood; 2005 Apr; 105(7):2891-9. PubMed ID: 15598810
[TBL] [Abstract][Full Text] [Related]
17. Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases.
Zhang YY; Peng J; Luo XJ
Biochem Pharmacol; 2022 Apr; 198():114977. PubMed ID: 35218741
[TBL] [Abstract][Full Text] [Related]
18. Identification of Tensin-3 as a MALT1 substrate that controls B cell adhesion and lymphoma dissemination.
Juilland M; Alouche N; Ubezzi I; Gonzalez M; Rashid HO; Scarpellino L; Erdmann T; Grau M; Lenz G; Luther SA; Thome M
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2301155120. PubMed ID: 38109544
[TBL] [Abstract][Full Text] [Related]
19. Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies.
Juilland M; Thome M
Curr Opin Hematol; 2016 Jul; 23(4):402-9. PubMed ID: 27135977
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.
Nagel D; Spranger S; Vincendeau M; Grau M; Raffegerst S; Kloo B; Hlahla D; Neuenschwander M; Peter von Kries J; Hadian K; Dörken B; Lenz P; Lenz G; Schendel DJ; Krappmann D
Cancer Cell; 2012 Dec; 22(6):825-37. PubMed ID: 23238017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
